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Abstract
The endocannabinoid system modulates numerous physiological processes including nociception and reproduction.
Anandamide (AEA) is an endocannabinoid that is inactivated by cellular uptake followed by intracellular hydrolysis by
fatty acid amide hydrolase (FAAH). Recently, FAAH-like anandamide transporter (FLAT), a truncated and
catalytically-inactive variant of FAAH, was proposed to function as an intracellular AEA carrier and mediate its
delivery to FAAH for hydrolysis. Pharmacological inhibition of FLAT potentiated AEA signaling and produced
antinociceptive effects. Given that endocannabinoids produce analgesia through central and peripheral mechanisms,
the goal of the current work was to examine the expression of FLAT in the central and peripheral nervous systems. In
contrast to the original report characterizing FLAT, expression of FLAT was not observed in any of the tissues
examined. To investigate the role of FLAT as a putative AEA binding protein, FLAT was generated from FAAH using
polymerase chain reaction and further analyzed. Despite its low cellular expression, FLAT displayed residual catalytic
activity that was sensitive to FAAH inhibitors and abolished following mutation of its catalytic serine. Overexpression
of FLAT potentiated AEA cellular uptake and this appeared to be dependent upon its catalytic activity.
Immunofluorescence revealed that FLAT localizes primarily to intracellular membranes and does not contact the
plasma membrane, suggesting that its capability to potentiate AEA uptake may stem from its enzymatic rather than
transport activity. Collectively, our data demonstrate that FLAT does not serve as a global intracellular AEA carrier,
although a role in mediating localized AEA inactivation in mammalian tissues cannot be ruled out.
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Introduction
The endocannabinoid anandamide (AEA) is an endogenous
ligand for cannabinoid receptors [1]. Through activation of
cannabinoid receptors, AEA regulates a plethora of biological
processes including nociception, inflammation, reproduction,
and gastric motility [2-4]. AEA signaling is terminated through
catabolism by the endoplasmic reticulum-localized enzyme
fatty acid amide hydrolase (FAAH) [5-7]. Prior to reaching
FAAH, lipophilic AEA requires transport through the aqueous
cytosol. To date, several intracellular AEA binding proteins
have been identified including fatty acid binding proteins
(FABPs), Hsp70, and most recently FAAH-like anandamide
transporter (FLAT) [8-10].
FLAT was reported to be a catalytically-silent truncated
(lacking residues 9-76) splice variant of FAAH that is co-
expressed with FAAH in mammalian tissues and cell-lines [10],
providing a possible mechanism to account for the efficient
uptake and inactivation of AEA in diverse tissues. Importantly,
inhibition of FLAT potentiated the antinociceptive effects of
AEA, suggesting that FLAT may represent a therapeutic target
[10]. Because previous reports have shown that the
antinociceptive effects of endocannabinoids may be mediated
by peripheral cannabinoid receptors [11], we sought to
ascertain whether FLAT is expressed in peripheral nerves and




AEA, URB597, FP-3845, and MAFP were from Cayman
Chemical (Ann Arbor, MI), fatty acid-free bovine serum albumin
was from Sigma, [14C]AEA (arachidonoyl-[1-14C]ethanolamide,
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60 mCi/mmol) was provided by the Drug Supply Program at the
National Institute on Drug Abuse.
Cell culture and transfections
HeLa and HEK-293 cells were grown in DMEM
supplemented with 10% fetal bovine serum, 100 units/ml
penicillin/streptomycin, 2 mM L-glutamine, and 1 mM sodium
pyruvate. The cells were transfected with FAAH, FLAT, green
fluorescent protein (GFP)-tagged FAAH (FAAH-GFP), or
plasma membrane-localized GFP (PM-GFP) using the GenJet
Plus reagent (SignaGen, Rockville, MD) according to the
manufacturer’s instructions. PM-GFP was previously described
[12] and was kindly provided by Deborah Brown (Stony Brook
University).
Immunofluorescence
HeLa cells were transfected with FAAH-FLAG, FLAT-FLAG,
PM-GFP, or FAAH-GFP. Immunolocalization of proteins was
performed exactly as described [9]. Following fixation and
permeabilization, cells were incubated with rabbit anti-FABP5
(1:500) (BioVendor R&D, Candler, NC), mouse anti-FAAH
(1:200) (Abcam, item #ab54615, immunogen: amino acids
480-580 of human FAAH), followed by donkey anti-rabbit 594
or goat anti-mouse 594 (Molecular Probes) antibodies. The
images were acquired using a Zeiss LSM 510 META NLO
Two-Photon Laser Scanning Microscope.
Western blotting
Western blotting was carried out exactly as described [9].
Membranes were probed with FAAH (1:400), β-actin (1:20,000)
(Abcam), or calnexin (1:5000) (Novus Biologicals) and
developed using the Immun-star HRP substrate (Bio-Rad) and
exposed to film.
Reverse transcription-polymerase chain reaction (RT-
PCR)
RT-PCR was carried out as described [13]. Briefly, cDNA
was prepared from RNA using the Superscript III first strand
synthesis system (Invitrogen) and subjected to PCR using
LongAmp Taq DNA polymerase (New England Biolabs) and
primers specific for the open reading frame of FAAH. The
following primers were used: forward 5’-
ATGGTGCTGAGCGAAGTGTG-3’ and reverse 5’-
AAGATGGCCGCTTTTCAGG-3’. The cycling conditions were
as follows: denaturation at 94°C for 30 sec, annealing at 58°C
for 30 sec, and extension at 65°C for 2 min for a total of 35
cycles.
Enzyme assays
FAAH and FLAT activity was determined as described
previously [9]. Briefly, cell homogenates were pretreated for 10
min with vehicle (1% ethanol) or inhibitors and subsequently
incubated with 30 μM [14C]AEA at 37°C for 5-30 min, ensuring
that substrate conversion remained at ~10-15%. Reactions
were stopped with two volumes of chloroform:methanol (1:1)
and the methanol phase was counted using a Beckman
LS6500 scintillation counter.
AEA uptake
Inhibition of AEA uptake into cells was performed exactly as
described [9]. FAAH, FLAT, or vehicle transfected HeLa cells
were incubated with 100 nM [14C]AEA for 5 min or 3 sec at
37°C. AEA uptake was quantified as previously described [9].
Statistics
Results represent means ± SE of at least three independent
experiments performed in triplicate. Statistical significance was
determined using two-tailed unpaired t tests or one-way
ANOVA followed by Dunnett’s post hoc analysis against the
corresponding controls.
Results
Expression of FLAT in mouse tissues
Antinociceptive effects of endocannabinoids are mediated by
both centrally and peripherally expressed cannabinoid
receptors [11,14-16]. While FAAH inhibitors reduce nociception
through central and peripheral FAAH inhibition [14,17], it is
currently not known whether FLAT regulates nociception at
peripheral or central sites. To address this, we examined the
expression of FLAT in mouse brain, spinal cord, and L3-L5
dorsal root ganglia (DRG). Surprisingly, RT-PCR analysis failed
to detect FLAT in these tissues while FAAH expression was
readily observed (Figure 1A). We extended our analysis to
other peripheral tissues but again failed to detect FLAT (Figure
1B). To determine whether FLAT expression could be
observed at the protein level, we performed western blotting
using an antibody raised against the C-terminus of FAAH (see
Methods), which is expected to also detect FLAT. Similar to the
RT-PCR results, our analysis revealed the presence of FAAH
but failed to detect FLAT in mouse brain regardless of the
protein concentration used (Figure 1C). Similar results were
observed in other mouse tissues (Figure 1D).
To permit further analyses of FLAT, we constructed rat FLAT
by removing residues 9-76 from FAAH. In contrast to FAAH,
FLAT was relatively poorly expressed upon transfection into
HeLa or HEK-293 cells (Figure 2A and B). Attempts to increase
FLAT expression using alternate cell-lines did not improve
expression levels (data not shown), suggesting that FLAT may
be an intrinsically unstable protein. Using transfected FLAT as
a guide, we confirmed that the mouse brain lacks FLAT
expression (Figure 2A). Analysis of FLAT expression was
extended to two cell-lines, mouse N18TG2 neuroblastoma and
human CCF-STTG1 astrocytoma cells. In agreement with
previous work [7], FAAH expression and activity was observed
in N18TG2 cells but was absent in CCF-STTG1 cells (Figure
2A and C). In contrast, FLAT expression was not observed in
either cell-type.
Functional Analysis of FLAT
The catalytic activity of FLAT was also examined. Despite its
low expression, FLAT possessed detectable enzymatic activity
that was sensitive to inhibition by the FAAH inhibitors URB597,
PF-3845, and MAFP, although complete inhibition was never
observed (Figure 3A and B). Normalization of FLAT activity to
FLAT and Anandamide Inactivation
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its expression level relative to FAAH revealed that FLAT
displays ~20% of the catalytic activity of FAAH at physiological
substrate concentrations (Figure 3C). Further kinetic analysis
demonstrated that FLAT hydrolyzes AEA with a Km of 25.3 ±
14.2 µM and Vmax of 0.29 ± 0.13 nmol/mg/min (Figure 4D). We
next examined whether FLAT modulates AEA cellular uptake
given that AEA uptake is known to be potentiated in cells
expressing catalytically competent FAAH, whose enzymatic
activity maintains an inward AEA concentration gradient
[13,18-20]. Overexpression of FLAT modestly potentiated AEA
Figure 1.  Expression of FAAH and FLAT in mouse tissues.  (A) RT-PCR analysis of FAAH and FLAT expression in mouse
brain, spinal cord, and L3-L5 DRG. Transcripts representing full-length FAAH (~1740 base pair fragments) were found in all tissues
examined. In contrast, FLAT (~1540 base pair fragment) was not detected in any of the tissues. (B) RT-PCR analysis of FAAH and
FLAT expression in mouse tissues. (C) Western blot demonstrating the expression of FAAH (~63 kDa) in mouse brain. Increasing
the amount of brain tissue from 5 to 25 µg did not reveal the presence of FLAT, which has an expected molecular weight of ~56
kDa. FAAH-transfected HeLa cells are also shown. (D) Western blot of FAAH expression in a panel of mouse tissues.
doi: 10.1371/journal.pone.0079355.g001
Figure 2.  Expression of FAAH and FLAT in cell-lines.  (A) Western blot of FAAH and FLAT expression in brain, HeLa cells
transfected with FAAH (0.15 µg) or FLAT (1.5 µg), and in N18TG2 neuroblastoma and CCF-STTG1 astrocytoma cells. (B)
Expression of FAAH and FLAT following transfection into HEK-293 cells. (C) AEA hydrolysis in homogenates of N18TG2, CCF-
STTG1, and HeLa cells (n = 3).
doi: 10.1371/journal.pone.0079355.g002
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uptake and although the inclusion of URB597 did not reduce
AEA uptake, a trend for reduced accumulation was observed
(Figure 3E). Indeed, the magnitude of FLAT-potentiated AEA
uptake was considerably lower than that observed with FAAH,
presumably a result of its low expression level. To confirm that
FLAT potentiates AEA uptake by hydrolyzing internalized AEA,
we mutated its catalytic serine to alanine. The expression
levels of FLAT and its S241A mutant (using labeling
nomenclature from FAAH) were similar (Figure 3F). As
expected, FLAT bearing the S241A mutation was catalytically
inactive (Figure 3G). Overexpression of wild-type FLAT in cells
potentiated AEA transport and this effect was lower in cells
expressing S241A FLAT, although again it did not reach
statistical significance (Figure 3H).
Lastly, we explored the subcellular localization of FLAT.
FAAH localizes to the endoplasmic reticulum and does not co-
localize with the plasma membrane marker PM-GFP (Figure 4)
[7]. Similar to FAAH, FLAT was distributed on intracellular
membranes and did not co-localize with PM-GFP (Figure 4). In
contrast, the intracellular AEA binding protein FABP5 was
distributed throughout the cytoplasm and regions of co-
localization with PM-GFP were observed.
Figure 3.  Effect of FLAT upon AEA hydrolysis and uptake.  (A) AEA hydrolysis by HeLa cell homogenates transfected with
FAAH or FLAT. Inset: Close up of AEA hydrolysis by FLAT-transfected and vector-transfected HeLa homogenates (n = 3). (B)
Inhibition of FAAH and FLAT by URB597, PF-3845, and MAFP. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (n = 3-5). (C) AEA (100 nM)
hydrolysis by FLAT normalized to its expression level relative to FAAH (n = 3). (D) FLAT hydrolyzes AEA (0.1-100 µM) with a Km of
25.3 ± 14.2 µM and Vmax of 0.29 ± 0.13 nmol/mg/min (n = 3-5). (E) AEA uptake in HeLa cells transfected with FAAH or FLAT in the
absence or presence of URB597. *, p < 0.05 (n = 3). (F) Western blot showing equal expression of WT and S241A FLAT in HeLa
cells. (G) Enzymatic activity of WT and S241A FLAT. (H) AEA uptake in HeLa cells expressing WT or S241A FLAT (n = 3).
doi: 10.1371/journal.pone.0079355.g003
FLAT and Anandamide Inactivation
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Discussion
Signaling lipids often depend on specialized transport
systems to ensure efficient ligand delivery and disposal. For
example, prostaglandins are thought to utilize plasma
membrane-localized transporters to traverse biological
membranes [21,22]. In contrast to such charged lipids,
endocannabinoids are uncharged and more lipophilic and
readily cross synthetic [23,24] and biological membranes
[20,25,26], although the existence of an endocannabinoid
transmembrane transporter has also been proposed [27]. In
contrast, the aqueous cytosol presents a diffusional barrier that
can be overcome through carrier-assisted intracellular
transport. AEA uptake is observed in a wide array of cell types
suggesting that proteins that mediate AEA uptake should
exhibit broad tissue distribution (for review, see 28,29). FABPs
and Hsp70s fit such a criterion as they are found in numerous
tissues and cell-types [30,31]. FLAT was also reported as a
widely expressed intracellular binding protein that selectively
transports AEA and likewise fits such criteria [10].
Endocannabinoids produce analgesia through central and
peripheral mechanisms [2,11,14]. Because pharmacological
inhibition of FLAT potentiated AEA-mediated analgesia in vivo
[10], the primary motivation for this manuscript was to
investigate the expression of FLAT in peripheral nerves. Using
RT-PCR and western blotting, we were unable to detect FLAT
expression in DRGs nor in other tissues examined, possibly
suggesting that FLAT may exhibit a low tissue expression
Figure 4.  Localization of FLAT in HeLa cells.  Subcellular
distribution of FAAH, FLAT, and FABP5 in cells. FAAH and
FLAT do not co-localize with the plasma membrane marker
PM-GFP while FABP5 does. In contrast, FAAH and FLAT are
distributed on intracellular membranes.
doi: 10.1371/journal.pone.0079355.g004
profile that is below the detection limit of these approaches.
These data are in contrast to the findings of Fu et al. who
observed robust FLAT expression throughout the brain [10].
The reason for this discrepancy is unclear. One possibility is
the use of different antibodies (i.e., monoclonal antibodies in
this manuscript vs. polyclonal FAAH antibodies by Fu et al.).
Confidence in the specificity of our approach is strengthened
by the finding that FAAH was not detected in a cell-line known
to be devoid of FAAH expression and activity. Furthermore, the
presence of a single band corresponding to FAAH in western
blots is supported by previous studies [6,32-36].
FLAT was reported to be a catalytically silent splice variant of
FAAH [10]. Our present data are mostly in agreement with
these results given the extremely low catalytic activity of FLAT.
Although our results suggest that this residual activity may
contribute towards AEA uptake, our analysis was hampered by
the low expression level of FLAT and did not yield a definitive
answer. Pharmacological inhibition of FLAT with ARN272 was
shown to potentiate AEA signaling and produces analgesia
[10]. Therefore, how can one reconcile our inability to detect
FLAT with such profound antinociceptive effects observed
following FLAT inhibition? One possibility is that FLAT may be
strategically expressed in brain regions that modulate pain
such as the periaqueductal gray, a region known to express
FAAH [37,38]. Such a low level and localized expression
pattern may have eluded our detection, which focused upon
global FLAT expression. Alternatively, ARN272 may target
proteins distinct from FLAT that regulate AEA inactivation and
AEA-mediated analgesia.
There are numerous outstanding questions regarding this
intriguing protein that merit further exploration. For example,
FAAH is a promiscuous enzyme that hydrolyzes numerous N-
acylethanolamines in addition to AEA [39-41]. In contrast,
FLAT has been reported to display an unprecedented
selectivity for AEA [10]. Similarly, while FAAH does not interact
with putative AEA transport inhibitors bearing oleoyl acyl chains
such as OMDM1 ((S)-N-oleoyl tyrosinol) [20,42], FLAT does.
Collectively, our results demonstrate that FLAT is not widely
expressed in mammalian tissues, indicating that it is unlikely to
serve as a global intracellular endocannabinoid carrier but may
instead mediate regional AEA inactivation.
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